Tracy Saxton is an Investment Director with the Roche Venture Fund (RVF). She currently serves on the boards of Lumos Pharmaceuticals, SutroVax Inc, Mission Therapeutics, Millendo Therapeutics and Purigen Biosystems. Prior to joining RVF, Dr. Saxton was at SV Life Sciences where she was involved in the financings of multiple biopharmaceutical companies including Ophthotech (OPHT), Catabasis (CATB), and Rempex (acquired by the Medicines Company). Dr. Saxton previously held positions at Tularik/Amgen, Threshold and Geron. She began her career as a drug discovery scientist and moved to leadership roles in regulatory affairs, business development and project/alliance management. Dr. Saxton earned her PhD in Medical Genetics from the University of Toronto, her MBA from Columbia University and was a Damon Runyon-Walter Winchell Cancer Fund fellow at UCSF.